



15864 US PTO
 0/827111

041904

17638 U.S.P.T.O.
 041904

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No.: 13099.0023U2 First Inventor: TACHDJIAN <i>et al.</i> Title: "SUBSTITUTED DIHYDRONAPHTHALENE AND ISOCHROMAN COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS, CANCER AND OTHER DISEASES" Express Mail Label No.: EL992076016US	
APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility application contents</small>		Mail Stop PATENT APPLICATION ADDRESS TO: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
1. <input checked="" type="checkbox"/> Specification [Total Pages 101] <small>(Includes application cover sheet, description, claims, and abstract)</small>		6. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large tables or Computer Program (Appendix)	
2. <input checked="" type="checkbox"/> Drawings [Total Sheets 14]		ACCOMPANYING APPLICATION PARTS:	
3. <input type="checkbox"/> Oath or Declaration [Total Pages _____] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 20B completed)		7. <input type="checkbox"/> Copy of Assignment 8. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) 9. <input type="checkbox"/> Power of Attorney 10. <input type="checkbox"/> English Translation Document (if applicable) 11. <input type="checkbox"/> Information Disclosure Statement/PTO-1449 <input type="checkbox"/> Copies of IDS Citations [Total Citations _____]	
4. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 <small>[Total Pages _____]</small>		12. <input type="checkbox"/> Preliminary Amendment 13. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 14. <input type="checkbox"/> Nonpublication Request under 35 USC 122(b)(2)(B)(i) <small>(Must attach form PTO/SB/35 or equivalent)</small>	
5. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Form (CRF) —OR— <input type="checkbox"/> Statement under 37 CFR 1.821(e) (see Box 21 for statement) b. <input type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper [Total Pages _____] c. <input type="checkbox"/> The contents of the computer readable form of the sequence listing and the sequence listing in the specification of the application are the same.		15. <input checked="" type="checkbox"/> Authorization to Treat Reply Requiring Extension of Time as Incorporating Petition for Extension of Time (2 pages) 16. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) 17. <input type="checkbox"/> Other: _____ _____ _____	
18. The FILING FEE is calculated as follows: (Claims as filed, less any claims cancelled by Amendment)			
Claims	Number Filed	Number Extra	Rate
Total claims	53 - 20 =	33	X \$18.00
Independent claims	2 - 3 =	0	X \$86.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ 290.00
TOTAL OF ABOVE CALCULATIONS =			\$1,364.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees are reduced by ½.			\$0.00
TOTAL FILING FEE =			\$1,364.00

20A.	<input checked="" type="checkbox"/>	This application is an original application (<u>not</u> a continuation, divisional or continuation-in-part) claiming priority under 35 U.S.C. § 111(b) of U.S. Provisional Application Serial No. 60/464,388, filed April 18, 2003.	
20B.	<input type="checkbox"/>	This application is a <input type="checkbox"/> continuation-in-part / <input type="checkbox"/> continuation / <input type="checkbox"/> divisional of prior Application No. _____. The prior application was assigned to Examiner _____, Group Art Unit _____. The entire disclosure of the prior application is considered a part of the disclosure of the accompanying application and is hereby incorporated by reference.	
	<input type="checkbox"/>	This application is a continuation or divisional application (<u>not</u> a continuation-in-part) that: (i) names as inventors the same or fewer than all the inventors named in the prior application; and (ii) contains no matter that would have been new matter in the prior application; and (iii) a copy of the executed oath or declaration in the prior application, showing the signature or an indication thereon that it was signed: <input type="checkbox"/> is enclosed. <input type="checkbox"/> will follow.	
	<input type="checkbox"/>	This application is a continuation or divisional application (<u>not</u> a continuation-in-part) that is being filed by less than all the inventors named in the prior application. In accordance with 37 C.F.R. §1.63(d)(2), the Commissioner is requested to delete the name(s) of the following person who are not inventors of the invention being claimed in this application: _____ <input type="checkbox"/>	
	<input type="checkbox"/>	This application is a continuation-in-part, continuation or divisional application naming an inventor not named in the prior application. A newly executed oath or declaration: <input type="checkbox"/> is enclosed. <input type="checkbox"/> will follow.	
21.	<input type="checkbox"/>	A sequence listing in computer readable form in compliance with 37 C.F.R. §§ 1.821-1.825 was submitted on _____ in prior Application No. _____, filed _____. Pursuant to 37 C.F.R. § 1.821(e), applicant hereby requests that the computer readable form of the sequence listing submitted in the above-referenced prior application be used as the computer readable form of the sequence listing for the new application. The paper or compact disk copy of the Sequence Listing in the new application is identical to the computer readable copy filed in the prior application.	
22.	<input type="checkbox"/>	This application claims foreign priority benefits under 35 USC 119(a)-(d) or 365(b) of any foreign application(s) listed below, or under 35 USC 365(a) or 365(b) of any PCT application listed below. Application No. _____ Country: _____ Day/Month/Year Filed: _____	
23. Address all correspondence to the address associated with:		Mark A. Murphy, Ph.D.	CUSTOMER NO. 23859
Name of Attorney/Agent:		Mark A. Murphy, Ph.D.	
Signature:		 Date: April 19, 2004	
Certificate of Express Mailing Under 37 C.F.R. § 1.10			
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL992076016US, in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.			
 Mark A. Murphy, Ph.D.		Date: 	



17638 U.S.PTO

ATTORNEY DOCKET NO. 13099.0023U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
)
TACHDJIAN et al.) Confirmation No.: Unassigned
)
Application No.: Unassigned) Group Art Unit: Unassigned
)
Filing Date: Concurrently) Examiner: Unassigned
)
FOR: "SUBSTITUTED DIHYDRONAPHTHALENE)
AND ISOCHROMAN COMPOUNDS FOR THE)
TREATMENT OF METABOLIC DISORDERS,)
CANCER AND OTHER DISEASES")

AUTHORIZATION TO TREAT REPLY REQUIRING EXTENSION OF TIME
AS INCORPORATING PETITION FOR EXTENSION OF TIME

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

April 19, 2004

Sir:


Pursuant to 37 C.F.R. §1.136(a)(3), the Commissioner is hereby requested and authorized to treat any concurrent or future reply in the above-identified application, requiring a petition for an extension of time for its timely submission, as incorporating a petition for extension of time

ATTORNEY DOCKET NO. 13099.0023U2
PATENT

for the appropriate length of time.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.



Mark A. Murphy, Ph.D.
Registration No. 42,915


NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300 Phone
(678) 420-9301 Fax

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL992076016US, in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.



Mark A. Murphy, Ph.D.



Date